MyMatrixx by Evernorth

04/16/2026

Presumptive coverage is giving injured workers access to care for several disease states and illnesses. In this WorkCompWire Leaders Speak article, you'll learn how is ensuring they also get the right care with a treatment plan that is safe and effective for the patient, while controlling costs for the payer. Learn more:

Alan Rook: From Pain Management to Whole Person Health July 29, 2025 - WorkCompWireWorkers’ Compensation Can Deliver More Than Medication By Alan Rook, Senior Clinical Account Executive, MyMatrixx by Evernorth For the past few years, there has been an influx of presumptive coverage legislation rel...

04/15/2026

Migraines are a serious neurological condition that can cause a profound disruption to daily life. Claims that include treatment for migraines can be complex and difficult to manage. Register now for this one-hour continuing education webinar to review medications to treat and prevent migraines, including dosing considerations, warnings, and common side effects. https://bit.ly/3Q5g0n1

04/10/2026

Many states are considering legislation that targets pharmacy benefit managers (PBMs). Several of these bills conflict with the state's existing workers' comp laws and may lead to higher medication costs. https://bit.ly/3Uq3dtX

04/10/2026

On April 1, 2026, the FDA approved Eli Lilly and Company's Foundayo™ - a treatment for chronic weight management. The once-daily, oral medication is available for adults with obesity or overweight adults with at least one weight-related medical condition. Find out more in our latest https://bit.ly/4miEaGD

04/09/2026

The California Division of Workers' Compensation has adopted updates to its Medical Treatment Utilization Schedule (MTUS) Drug List. The latest updates, effective April 30, 2026, add two-exempt migraine medications. Read more https://bit.ly/4tyRIAg

04/02/2026

ODG by MCG has adopted changes to the Drug Formulary, which lists FDA-approved drugs commonly prescribed for workplace injuries. The latest updates, effective April 3, 2026, change two previously N drugs to Y drugs. https://bit.ly/4uXfqrv

03/23/2026

Last chance to register for our next CE webinar! MyMatrixx experts Courtney Deck and Adam Fowler will explain presumptive illnesses common in workers’ compensation and the states proposing legislative actions for new or expanding presumptive coverage. Register NOW! https://bit.ly/3YLfUlN

03/17/2026

One more week to register for our next CE webinar! MyMatrixx experts Courtney Deck and Adam Fowler will explain presumptive illnesses common in workers’ compensation and the states proposing legislative actions for new or expanding presumptive coverage. Register NOW! https://bit.ly/3YLfUlN

03/10/2026

Presumptive claims in workers’ compensation require a new approach to care that focuses on treating long-term disease management. Register now for this one-hour continuing education webinar to review common presumptive illnesses and the medications associated with them. We will also review what states are proposing legislative actions for new or expanding presumptive coverage. https://bit.ly/3YLfUlN

03/04/2026

On February 25, 2026, the First District Court of Appeal in Florida issued their long-awaited opinion, which declared dispensing practitioners are not pharmacists. This ruling invalidated physician dispensing regulations previously adopted by the Florida DWC and has implications for injured worker choice, payer authorization and provider reimbursement. Read more https://bit.ly/4aNrh3t

03/03/2026

Visit mymatrixx.com to register for the MyMatrixx 2026 quarterly continuing education webinars. Fill your calendar with our great topics that will help you better manage your claims. Plus, you’ll have the opportunity to earn CE credits! Register NOW! https://www.mymatrixx.com/thought-leadership/continuing-education-webinars

02/24/2026

On February 4, 2026, the FDA approved Novo Nordisk's Ozempic® oral tablets for use in adults with type 2 diabetes. The lower dose tablets simplify the semaglutide-based treatment options, replacing the use of Rybelsus®. Find out more in our latest https://bit.ly/46Vwi7t